NZ528624A - Antibodies against cancer - Google Patents

Antibodies against cancer

Info

Publication number
NZ528624A
NZ528624A NZ528624A NZ52862402A NZ528624A NZ 528624 A NZ528624 A NZ 528624A NZ 528624 A NZ528624 A NZ 528624A NZ 52862402 A NZ52862402 A NZ 52862402A NZ 528624 A NZ528624 A NZ 528624A
Authority
NZ
New Zealand
Prior art keywords
antibody
cancer
fragment
monoclonal
antibodies against
Prior art date
Application number
NZ528624A
Other languages
English (en)
Inventor
Ian Farquar Campbell Mckenzie
Pei-Xiang Xing
Original Assignee
Austin Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Austin Research Inst filed Critical Austin Research Inst
Publication of NZ528624A publication Critical patent/NZ528624A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ528624A 2001-03-26 2002-03-26 Antibodies against cancer NZ528624A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR3958A AUPR395801A0 (en) 2001-03-26 2001-03-26 Antibodies against cancer
PCT/AU2002/000362 WO2002077033A1 (en) 2001-03-26 2002-03-26 Antibodies against cancer

Publications (1)

Publication Number Publication Date
NZ528624A true NZ528624A (en) 2006-03-31

Family

ID=3827964

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ528624A NZ528624A (en) 2001-03-26 2002-03-26 Antibodies against cancer

Country Status (9)

Country Link
US (1) US7318924B2 (enExample)
EP (1) EP1383801A4 (enExample)
JP (2) JP4854912B2 (enExample)
KR (1) KR100909290B1 (enExample)
CN (2) CN100457781C (enExample)
AU (3) AUPR395801A0 (enExample)
CA (1) CA2442318A1 (enExample)
NZ (1) NZ528624A (enExample)
WO (1) WO2002077033A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0020953D0 (en) 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
US7582299B2 (en) 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
RS20110024A (sr) 2001-04-26 2011-08-31 Biogen Idec Ma Inc. Antitela koja blokiraju cripto i njihova upotreba
AU2003301619A1 (en) * 2002-10-23 2004-05-13 Exelixis, Inc. MBMs AS MODIFIERS OF BRANCHING MORPHOGENESIS AND METHODS OF USE
US7824872B2 (en) 2003-04-03 2010-11-02 Theravalues Corporation Pharmaceutical agents
US20050163782A1 (en) * 2003-06-27 2005-07-28 Biogen Idec Ma Inc. Modified binding molecules comprising connecting peptides
AU2004274433B2 (en) * 2003-09-15 2010-08-12 Research Development Foundation Cripto antagonism of activin and TGF-beta signaling
WO2005037293A1 (en) 2003-10-16 2005-04-28 Univ Monash Immunomodulating compositions and uses therefor
EP2311881A3 (en) * 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto binding molecules
US7939056B2 (en) * 2005-11-14 2011-05-10 The Brigham And Women's Hospital, Inc. Interleukin-10 compositions for the treatment of adenocarcinomas
CA2688563A1 (en) * 2007-06-01 2008-12-11 Biogen Idec Ma Inc. Cripto binding molecules
EP3156069B8 (en) 2008-06-20 2020-10-21 Duke University Compositions, methods, and kits for eliciting an immune response
KR100973029B1 (ko) * 2008-10-07 2010-08-11 박지운 알루미늄 합금 가로등 등주
EP2350131B1 (en) * 2008-11-07 2017-06-07 Research Development Foundation Compositions and methods for the inhibition of cripto/grp78 complex formation and signaling
WO2012105219A1 (ja) * 2011-01-31 2012-08-09 オリンパス株式会社 抗体療法の効果増強剤
KR102023496B1 (ko) 2011-04-21 2019-09-20 시애틀 지네틱스, 인크. 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도
MX380273B (es) 2013-12-23 2025-04-01 Bayer Pharma AG Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
US11198738B2 (en) * 2015-04-20 2021-12-14 Minomic International Ltd. Therapeutic antibodies and uses thereof
SG10201908685QA (en) 2015-06-22 2019-10-30 Bayer Pharma AG Antibody drug conjugates (adcs) and antibody prodrug conjugates (apdcs) with enzymatically cleavable groups
EP3313523A2 (en) 2015-06-23 2018-05-02 Bayer Pharma Aktiengesellschaft Targeted conjugates of ksp inhibitors
WO2017060322A2 (en) 2015-10-10 2017-04-13 Bayer Pharma Aktiengesellschaft Ptefb-inhibitor-adc
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
CA3027445A1 (en) 2016-06-15 2017-12-21 Bayer Pharma Aktiengesellschaft Specific antibody-drug-conjugates (adcs) with ksp inhibitors and anti-cd123-antibodies
CA3047522A1 (en) 2016-12-21 2018-06-28 Bayer Pharma Aktiengesellschaft Specific antibody drug conjugates (adcs) having ksp inhibitors
EP3558386A1 (de) 2016-12-21 2019-10-30 Bayer Aktiengesellschaft Prodrugs von cytotoxischen wirkstoffen mit enzymatisch spaltbaren gruppen
JP7066714B2 (ja) 2016-12-21 2022-05-13 バイエル・ファルマ・アクティエンゲゼルシャフト 酵素的に切断可能な基を有する抗体薬物コンジュゲート（ａｄｃ）
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
JP6761889B1 (ja) * 2019-11-11 2020-09-30 株式会社Ｇｓｐエンタープライズ 抗ヒトＣｒｉｐｔｏ−１抗体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5171665A (en) * 1989-04-17 1992-12-15 Oncogen Monoclonal antibody to novel antigen associated with human tumors
US5256643A (en) * 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
US5264557A (en) * 1991-08-23 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Polypeptide of a human cripto-related gene, CR-3
US5981215A (en) * 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
ES2312177T3 (es) * 1996-05-22 2009-02-16 Viventia Biotech Inc. Fragmentos de union a antigenos que detectan especificamente celulas cancerosas, nucleotidos que codifican los fragmentos y el uso de los mismos para la profilaxis y deteccion de canceres.
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
CA2358420C (en) * 1999-03-11 2010-03-16 Ardenia Investments Ltd. New compounds for the treatment of cancer
US6333410B1 (en) * 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
GB0020953D0 (en) * 2000-08-24 2000-10-11 Smithkline Beecham Biolog Vaccine
AU2001292724B2 (en) * 2000-09-18 2005-05-26 Biogen Idec Ma Inc. CRIPTO mutant and uses thereof
US7582299B2 (en) * 2001-04-26 2009-09-01 Biogen Idec Ma Inc. Cripto-specific antibodies
RS20110024A (sr) 2001-04-26 2011-08-31 Biogen Idec Ma Inc. Antitela koja blokiraju cripto i njihova upotreba

Also Published As

Publication number Publication date
KR20040010613A (ko) 2004-01-31
US7318924B2 (en) 2008-01-15
WO2002077033A1 (en) 2002-10-03
AU2007201587A1 (en) 2007-05-03
US20040176576A1 (en) 2004-09-09
EP1383801A1 (en) 2004-01-28
CN101310770A (zh) 2008-11-26
JP2004534741A (ja) 2004-11-18
AU2002240719B2 (en) 2007-01-11
EP1383801A4 (en) 2005-06-01
AUPR395801A0 (en) 2001-04-26
CA2442318A1 (en) 2002-10-03
JP4854912B2 (ja) 2012-01-18
CN1639194A (zh) 2005-07-13
JP2009024014A (ja) 2009-02-05
KR100909290B1 (ko) 2009-07-24
CN100457781C (zh) 2009-02-04

Similar Documents

Publication Publication Date Title
NZ528624A (en) Antibodies against cancer
RU2008128244A (ru) Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2
IL161686A0 (en) Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2004032857A3 (en) Antibody therapy
JP2004534741A5 (enExample)
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
NZ568769A (en) Human monoclonal antibodies against CD20
NZ572756A (en) Deimmunized antagonistic anti-human cd40 monoclonal antibody from the ch5d12 antibody
NZ596878A (en) Methods of administering anti-tnfalpha antibodies
CA2383493A1 (en) Treating prostate cancer with anti-erbb2 antibodies
NO20091792L (no) Anvendelse av antistoff som binder til ErbB2 og blokkerer ligandaktivering av en ErbB2-reseptor, for fremstilling av et medikament for behandling av kreft hos et menneske, anvendelse av rhuMAb 2C4 for fremstilling av et medikament for behandling av kreft, humanisert antistoff, immunkonjugat, affinitetsmodnet antistoff
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
GEP20084484B (en) Antibodies to insulin-like growth factor i receptor
TR200102845T2 (tr) Kanserlerin iyileştirilmesi için RHUMAB HER2 ile birlikte dosetaksel
ATE471946T1 (de) Humanisierter antikörper (h14.18) des maus antikörpers 14.18, der gd2 bindet und seine fusion mit il-2
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
TW200517124A (en) Fully human antibodies against human 4-1BB
PL1684770T3 (pl) Oligo-beta-(1,3)-glukan i przeciwrakowe przeciwciała monoklonalne
WO2024062072A3 (en) Anti-ccr8 monoclonal antibodies and their therapeutic use
EP2641611A3 (en) Combination therapy

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed